ActX
ActX, founded in 2012, provides EHR-integrated genomic decision support through its GenoACT platform. The system automatically checks prescriptions against patient genetics and identifies actionable hereditary risks for health systems, practices, and patients across 10+ major EHR platforms.
- Company typePrivate
- Founded2012
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What ActX does
ActX, Inc. is a Seattle-based, privately-held precision medicine company founded in 2012 by Dr. Andrew Ury that operates a cloud-based genomic decision support platform called GenoACT, natively integrated into Electronic Health Record systems via SMART on FHIR standards. The platform processes saliva-collected genetic samples through a CLIA-certified, CAP-accredited laboratory, covering 600,000 genetic variants and 230+ carrier conditions, then automatically checks prescriptions against patient genetics for adverse reactions, efficacy, and dosing, while surfacing actionable hereditary risks within the clinician's existing EHR workflow. An evidence-based KnowledgeBase — curated by clinicians, geneticists, genetic counselors, and clinical pharmacists and continuously updated as new research emerges — powers the underlying clinical logic.
ActX generates revenue through multiple streams: direct-to-patient genetic testing paid out-of-pocket (with HSA/FSA eligibility, not insurance-covered), a $95 medical interpretation service for existing 23andMe customers, quote-based enterprise subscription licensing to health systems and physician practices, and laboratory reporting services sold to other clinical laboratories. Distribution is hybrid, combining direct enterprise field sales, EHR partner marketplaces (Epic App Orchard, athenahealth Marketplace, Oracle Cloud Marketplace, Greenway Marketplace, etc.), and direct-to-consumer sign-up with physician authorization. The company has accumulated 15+ named health system customers including NorthShore, Yale New Haven Health, Baptist Health, Nemours, Cone Health, Mount Sinai, Vancouver Clinic, Lakeland Regional Health, Nicklaus Children's, UAB Medicine, Ochsner, and St. Elizabeth, with integrations spanning 10+ major EHR platforms and an addressable footprint of 75,000+ providers via athenahealth and 100+ EHR systems via NewCrop.
The company is venture-backed only at the angel/early-stage scale (Alliance of Angels, Keiretsu Forum/Capital, Puget Sound Venture Club), with approximately $6.1 million total disclosed funding raised through a December 2022 SEC Form D filing, and an 11-50 employee headcount. It holds CAP laboratory accreditation (passed 2024 inspection with zero deficiencies), CLIA certification, HIPAA compliance, and TX-RAMP Level 2 certification, and has extended multi-year enterprise commitments (e.g., Baptist Health through 2028) and entered a CMS-funded dementia care program (GUIDE Initiative) in 2026.
ActX firmographics
Firmographics- Name
- ActX
- Legal name
- ActX, Inc.
- Website
- https://actx.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ActX, founded in 2012, provides EHR-integrated genomic decision support through its GenoACT platform. The system automatically checks prescriptions against patient genetics and identifies actionable hereditary risks for health systems, practices, and patients across 10+ major EHR platforms.
- Ownership category
- akta.pro rank
ActX industry classification
Industry- Product category
- Clinical Genomics Software
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Pharmacogenomics (PGx) Decision Support (HLAAANAB)
- akta.pro secondary industry
- Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH)
Keywords
Where ActX is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ActX business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Direct Patient Genetic Testing: Patients pay directly for the ActX service after physician authorization. Service includes pharmacogenomics, hereditary risk assessment, and carrier status screening. Currently not covered by insurance. HSA/FSA funds accepted.
- 23andMe Analysis Service: Interpretation service for 23andMe raw genetic data. Patients pay $95 for ActX analysis that provides more extensive coverage on medications, risks, and carrier conditions than standard 23andMe reports.
- Health System Enterprise Licensing: Health systems pay for enterprise-wide genomic decision support deployment. Includes EHR integration, provider access, and system-wide analytics. Implementation in weeks rather than years.
- Laboratory Reporting Services: Pharmacogenomic reporting services for other laboratories. Includes PDF PGX reports with customizable panels, CAP accredited genomic interpretation, and provider/patient portal options.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | 23andMe Analysis - One-time interpretation service |
| One time/ perpetual license | Pay-as-you-go | Full Service - Complete genomic screening |
| One time/ perpetual license | Pay-as-you-go | Pharmacogenomics Service - Medication-focused only |
| Subscription | Annual | Enterprise Health System Deployment |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels6 records
ActX product offering
Product offeringCore offering
ActX builds and operates GenoACT, an EHR-integrated genomic decision support platform that automatically checks prescriptions against patient genetics for drug-genome interactions, adverse reactions, efficacy, and dosing, while alerting physicians to actionable hereditary risks and carrier status. The company processes patient saliva samples through its CLIA-certified laboratory using micro-array testing covering 600,000 genetic variants, with continuously updated clinical interpretation delivered in real time inside the physician's existing EHR workflow.
Product overview
ActX offers a unified genomic decision support platform called GenoACT that provides precision medicine capabilities integrated into Electronic Health Records. The core product portfolio includes the GenoACT Genomic Decision Support platform, ActX Full Service (comprehensive pharmacogenomics, hereditary risks, carrier status), and ActX Pharmacogenomic Service (drug-genome interactions only). Supporting modules include a patient mobile app (My ActX Genomic Profile), Analytics Dashboard for population health insights, Laboratory Reporting services, Medications by Class visualization, Patient Genetic Testing Recommendations, Dosage and Route-Aware Clinical Alerting, and a Traits feature for non-medical genetic information. ActX also offers a 23andMe integration service for interpreting raw genetic data. The platform integrates with 10 major EHR systems including Epic, Oracle Health, Veradigm, and others via SMART on FHIR standards.
Differentiator
Problem solved
Functional benefit
Brands
- GenoACT: ActX's Genetic Clinical Decision Support Service that provides actionable genomic decision support within EHR workflow
- Actionable Genomics
- Genomic Decision Support
Products and services
- GenoACT Genomic Decision Support Core genomic decision support platform integrated into major EHR systems (Epic, Oracle Health, athenahealth, eClinicalWorks, Greenway, NextGen, Veradigm, Aprima, CompuGroup Medical, NewCrop) that automatically checks prescriptions against patient genetics for drug-genome interactions, adverse reactions, efficacy, and dosing, while alerting physicians to actionable hereditary risks and carrier status. Targeted at health systems, hospitals, and physician practices.
- ActX Full Service Comprehensive genomic screening service for individual patients covering pharmacogenomics (drug-genome interactions), hereditary risk assessment for actionable conditions, and carrier status screening for 230+ genetic diseases. Patients pay directly after physician authorization, with HSA/FSA eligibility.
- ActX Pharmacogenomic Service (PGx-only) Focused service providing only drug-genome interaction information and medication-related risks for patients who prefer not to receive non-medication hereditary risk information. Upgradeable to Full Service for a small fee.
- My ActX Genomic Profile Mobile App Free mobile application available on iOS and Android that allows patients to access their ActX Genomic Profile, check medications via Med Check functionality, view hereditary risks, and share results with healthcare providers.
- ActX Laboratory Reporting Service Pharmacogenomic reporting and interpretation service for clinical laboratories, offering PDF PGX reports with customizable panels, discrete genetic data file transmission (CSV/VCF), optional provider/patient portals, CAP-accredited genomic interpretation, and EHR integration capabilities for the lab's customers.
- ActX for 23andMe Medical genetic interpretation service for existing 23andMe customers, providing $95 analysis of raw 23andMe genetic data with more extensive coverage on medications, hereditary risks, and carrier conditions than standard 23andMe Health + Ancestry reports. The interpretation integrates into the patient's medical chart for physician use.
Quantifiable outcome
- 89-99% of patients carry variants affecting medications
- +4 more outcomes
Companies that use ActX
Customer profileNamed customers14 records
Segments6 records
Ideal customer profiles5 records
ActX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
AI capability3 records
Feature7 records
ActX partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered secondary, core and strategic.
- AprimasecondaryAprima Medical Software integration partnership to bring precision medicine into the physician's office. ActX provides genomic decision support integrated with Aprima EHR.
- CompuGroup Medical (CGM)coreActX partnered with CompuGroup Medical US to integrate real-time genomic decision support into CGM's EHR solutions (CGM webEHR and CGM CLINICAL). CGM Genomics powered by ActX branding. Provides prescription checking and actionable risk alerts within CGM EHR workflow.
- athenahealthcoreActX partnered through athenahealth's 'More Disruption Please' (MDP) program, making ActX part of the athenahealth Marketplace offerings. Links athenaClinicals with ActX capabilities to incorporate genomic decision support into existing physician workflow. Access to athenahealth's network of 75,000+ healthcare providers.
- Greenway HealthsecondaryActX joined Greenway Health online Marketplace as approved partner for PrimeSUITE EHR users. Certified Greenway Marketplace partner. Integration checks prescriptions against patient genetics within Greenway electronic chart.
- EpiccoreActX provides genomic decision support integrated into EpicCare EHR. Available through Epic App Orchard marketplace. ActX is integrated into Order Entry and Genomic tab, checking medications and alerting for actionable risks. Featured Epic customers include NorthShore, Yale New Haven Health, Baptist Health, and others. Epic President Carl Dvorak publicly endorsed ActX's integration capabilities.
- Oracle Health (Cerner)coreActX offers genomic decision support platform built for Oracle Health (Cerner EHR). Available as SMART on FHIR app through Oracle Cloud Marketplace. ActX is a validated Cerner Code developer partner. Provides real-time decision support, alerts for actionable genomic risks, integrated patient Genomic Profile, and customizable content.
- eClinicalWorkssecondaryActX integrated with eClinicalWorks EHR to bring precision medicine to patient care. Turn-key approach focusing on Actionable Genomics checking prescriptions for adverse reactions, efficacy, and dosing. Genomic Profiles accessible within eClinicalWorks patient chart.
- NextGen HealthcaresecondaryActX partnered with NextGen to make genomic decision support available within NextGen EHR workflow. Identifies actionable hereditary risks and alerts clinicians in their inbox for 3-4% of patients with actionable risks.
- NewCropcoreActX partnered with NewCrop prescribing system and associated EHR partners. Integration means providers using 100+ partner EHR systems can see genetically-based alerts about medication efficacy, dosing, and adverse reactions. Access through NewCrop's extensive partner network.
- Veradigm (Allscripts)secondaryActX integrated with Veradigm EHR (formerly Allscripts) and Alterra TouchWorks. Brings Actionable Genomics into practices integrated into the electronic chart. Checks prescriptions and alerts for adverse effects, efficacy, dosing issues.
- NavRxstrategicCollaboration between ActX and NavRx for the GUIDE Dementia Care Initiative. ActX provides dynamic pharmacogenomics reporting for thousands of early dementia patients. Project incorporates pharmacogenomics and metabolomics for medication management, enabled by clinical pharmacists.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
ActX competitors and assessment
Company assessmentDirect peers
- Genomind: Pharmacogenomics testing and clinical decision support company offering GeneSight, a PGx panel integrated into mental-health prescribing workflows. Directly comparable to ActX as a PGx-CDS provider targeting clinicians for medication optimization.
- YouScript (by Streamline Health): Pharmacogenomics decision support platform providing drug-gene interaction alerts for prescribers, with EHR integration. Closely aligned with ActX's GenoACT value proposition of real-time PGx guidance within the prescribing workflow.
- Translational Software: PGx knowledge base and clinical decision support vendor that delivers pharmacogenomic interpretation to health systems and labs via APIs and EHR integrations. Comparable to ActX as a content + integration PGx-CDS competitor.
- 2bPrecise (an Allscripts/Veradigm-affiliated platform): Genomics clinical decision support platform originally built inside Allscripts, delivering precision-medicine insights inside the EHR. Direct functional competitor to ActX, particularly in the Veradigm/Allscripts ecosystem.
- Molecular Health: Clinical genomics decision support company providing treatment-guidance analytics based on molecular and genetic data. Comparable to ActX as an enterprise clinical genomics decision-support vendor for health systems.
- Coriell Life Sciences: Pharmacogenomics and precision medicine company offering enterprise PGx decision support for health systems and employee benefits. Comparable to ActX in serving large populations with PGx-CDS offerings.
Broad incumbents
- SOPHiA Genetics: Genomics analytics platform for hospitals and labs offering AI-driven interpretation across multiple testing areas. Broader-scope incumbent with overlapping clinical-decision-support capabilities for genomics, though more lab-oriented than EHR-prescribing-focused.
- Myriad Genetics: Large established genetics testing company with pharmacogenomics (GeneSight) and hereditary risk products. Broader incumbent offering overlap with ActX's PGx and hereditary-risk service lines, though via lab testing rather than primarily EHR-native CDS.
- Epic (Genomics Module / Cosmos): Dominant EHR vendor whose platform is the primary distribution channel for ActX. Represents both the largest go-to-market opportunity and the principal incumbent risk if Epic ships native genomics decision support to compete directly.
Others
- 23andMe: Consumer genetic testing company whose raw-data files are interpreted by ActX's $95 service. Adjacent partner rather than direct competitor — ActX monetizes 23andMe's installed base by providing medical-grade interpretation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
ActX social profiles
Digital presenceActX compliance and trust
Trust signalCompliance4 records
ActX financial estimates
Financial estimateRevenue estimate
Valuation estimate
ActX leadership team
Management profileNumber of profiles
Profiles3 records
ActX funding detail
Funding detailFunding overview
Funding rounds8 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ActX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ActX
What does ActX do?
ActX builds and operates GenoACT, an EHR-integrated genomic decision support platform that automatically checks prescriptions against patient genetics for drug-genome interactions, adverse reactions, efficacy, and dosing, while alerting physicians to actionable hereditary risks and carrier status. The company processes patient saliva samples through its CLIA-certified laboratory using micro-array testing covering 600,000 genetic variants, with continuously updated clinical interpretation delivered in real time inside the physician's existing EHR workflow.
Is ActX a public or private company?
ActX is a private company. It is classified as venture growth investor backed and is currently operating.
When was ActX founded?
ActX was founded in 2012. It employs 11 to 50 people.
Where is ActX based?
ActX is headquartered in Seattle, United States, in the North America region.
How does ActX make money?
Four revenue lines are on record. Direct Patient Genetic Testing is the primary driver. The others are 23andMe Analysis Service, health System Enterprise Licensing and laboratory Reporting Services.
Who are ActX's main competitors?
Direct peers on record are Genomind, YouScript (by Streamline Health), Translational Software, 2bPrecise (an Allscripts/Veradigm-affiliated platform), Molecular Health and Coriell Life Sciences. Broad incumbents are SOPHiA Genetics, Myriad Genetics and Epic (Genomics Module / Cosmos). 23andMe is listed as an others.
Does ActX have an API?
No public API is recorded for ActX.
What industry is ActX in?
ActX's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLACAKAH, Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools. Its NAICS code is 621511 and its SIC code is 8071.